In the domain of kidney transplantation, BPAR, which stands for Biopsy-Proven Acute Rejection, is an essential issue that has to be addressed and prevented. Modern pilot researches, which include the RIMINI and OSAKA trials, highlight certain distinctive characteristics of various immunosuppressive protocols.
In the RIMINI study group BPAR was much higher 22% and in the historical cohort the rate was unspecified. However, information concerning the immunosuppressants utilized in the historical data remains limited, which in turn poses a challenge to making pertinent comparisons.
On the other hand, the OSAKA study which used Tac , MMF and steroids presented
a BPAR of between 10-16%. Such contrast of situations suggests that there may
be advantages in applying the specific combination of a drugs which was used in
the experiment of OSAKA.
The consequences in the RIMINI study were unfavorable; there was graft loss and
five more cases of BPAR associated with poor graft function. This means that
the acute rejection episodes were not insignificant and that significant action
had to be taken with regard to them. In this respect, it is worth noting that
10 among the 13 acute rejection episodes defined in this study were clinically
manifested and confirmed histologically with help of biopsies, stressing the
clinical importance of these rejections. In the second year, three more cases
of Chronic Rejection (CR) were recorded, therefore signifying the hurdles that
the patients in the RIMINI cohort were to face.
Another important factor that was found in the research conducted as part of
the RIMINI study was the fact that dnDSAs were rarely tested routinely. It
could also be due to attentive scrutiny of the occurrence as opposed to a real
higher incidence of dnDSAs as seen above. However, dnDSAs are present, which is
undesirable, especially in the context of the MMF-avoidance regimen used in
RIMINI.
One year eGFR of Renal allografts is comparable between RIMINI, OSAKA and
CTOT-19. Overall, the results point out that retention of overall kidney
function was the same, meaning that while BPAR rates were different, there were
no major disparities.
Concerning the other outcomes including DGF, PNF and severe adverse events the
incidences in the present study were comparable to historical rates noted in
RIMINI trial. This suggests that use of BPAR was more prevalent in RIMINI, thus
not implying that other crucial results were compromised.
Therefore, elevated BPAR rate and appearance of dnDSAs in the RIMINI study
indicate that MMF avoidance may result in under-immunosuppression. Prior
attempts to minimize immunosuppressant medications have cost rejection rates
soaring with inferior outcomes reiterating the trials of eradicating or
decreasing immunosuppressant medications. In the modern day, the recommended
protocol of tacrolimus, MMF, and corticosteroids are still required to maintain
graft viability and optimize outcomes in kidney transplant recipients.
Reference - Concord Biotech Pvt. Ltd
Knowledge shared!!
⥁
Comments
Post a Comment